This summary was created by AI, based on 1 opinions in the last 12 months.
Evome Medical Technologies (EVMT-X) is transitioning from its previous identity as Salona Global Medical (SGMD-X) with a strategic focus on physiotherapy acquisitions. Despite accumulating significant debt, recent leadership changes have sparked positive momentum as the new management is actively working to reduce this burden by divesting certain divisions. Their aim is to eliminate all acquisition-related debt by late 2024 or early 2025, which is expected to bolster the company's financial health. The introduction of innovative, smaller, and tech-driven equipment is anticipated to facilitate increased sales volume. Additionally, with revenue showing signs of growth and EBITDA turning positive, experts suggest that the company is on a promising trajectory while also exploring opportunities beyond the North American market.
Evome Medical Technologies is a Canadian stock, trading under the symbol EVMT-X on the TSX Venture Exchange (EVMT-CV). It is usually referred to as TSXV:EVMT or EVMT-X
In the last year, there was no coverage of Evome Medical Technologies published on Stockchase.
Evome Medical Technologies was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Evome Medical Technologies.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
In the last year, there was no coverage of Evome Medical Technologies published on Stockchase.
On 2025-02-03, Evome Medical Technologies (EVMT-X) stock closed at a price of $0.105.
(Formerly Salona Global Medical, SGMD-X)
Acquisition strategy in physiotherapy, racked up a fair bit of debt. Market got concerned. New management, paying down some debt by selling off divisions. Goal is to get rid of all acquisition debt by late 2024/early 2025. New tech has made equipment smaller and more technology-driven, which will allow for mass sales.
Revenue ramping up, EBITDA has turned positive. Under the radar. Looking to do deals outside NA as well.